Great news from the NHS today, which we highlighted in August in our blog in relation to Niemann-Pick UK (NPUK): "The aim of this initiative (‘Screening Saves Lives’) was to raise awareness and ensure the UK government sees the benefit of adding more conditions to the UK newborn screening programme. Currently the blood spot/heel prick test checks for 9 rare conditions in the UK, far less than many other high-income countries. Italy for example, screen their babies for 43 conditions, Iceland 47, and the US up to 59." It is great to see that this study will look to increase the number of tests being conducted on newborns, especially for rare diseases, and we look forward to this being rolled out across the UK. Read our blog here: https://lnkd.in/eTzuZCiz More information on the study: https://lnkd.in/e_iVYB9C Find out about the newborn screening collaborative: https://lnkd.in/eWCJian5
Hundreds of newborns are now being tested for over 200 rare genetic conditions in a world-leading NHS study. It aims to screen up to 100,000 babies across England. The Generation Study, led by Genomics England and NHS England, uses whole genome sequencing to detect conditions like Metachromatic Leukodystrophy (MLD) early. This could help families, like Lucy and her son Joshua, access treatment sooner and improve lives. Joshua is nine years old and has Early Juvenile MLD, one of the 200 conditions being tested for in the study. His mum Lucy said, ‘It took two years for us to get a diagnosis because his condition was so rare. With earlier diagnosis, Josh could have benefitted from transformational gene therapy on the NHS, which would have been life-changing.’ I hope that this study will help other families and children access the treatment they need sooner.’ The study will also support broader research, improving testing and exploring how genome data could help predict, diagnose, and treat illnesses in the future. Read more about this groundbreaking study here: https://lnkd.in/e_iVYB9C #Genomics #Screening #MetachromaticLeukodystrophy #MLD